Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)

PHASE3CompletedINTERVENTIONAL
Enrollment

187

Participants

Timeline

Start Date

February 20, 2017

Primary Completion Date

January 31, 2019

Study Completion Date

May 17, 2021

Conditions
Advanced CholangiocarcinomaMetastatic Cholangiocarcinoma
Interventions
DRUG

AG-120

Tablet administered orally

DRUG

Placebo

Tablet administered orally

Trial Locations (49)

10021

Memorial Sloan-Kettering Cancer Center, New York

10032

Columbia University, New York

10060

Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS Candiolo), Candiolo

10408

National Cancer Center, Seoul

19111

Fox Chase Cancer Center, Philadelphia

20089

Istituto Clinico Humanitas, Rozzano

20127

Istituto Scientifico Universitario San Raffaele, Milan

21287

Johns Hopkins University, Baltimore

25000

Universite de Franche-Comte, Besançon

28007

Hospital General Universitario Gregorio Marañón, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

28050

Centro Integral Oncologico Clara Campal, Madrid

29303

Gibbs Cancer Center, Spartanburg

32224

Mayo Cancer Center, Jacksonville

33076

Centre de Lutte Contre le Cancer (CLCC) - Institut Bergonie, Bordeaux

35042

Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer, Rennes

37203

Sarah Cannon Research Institute, Nashville

37232

Vanderbilt University Medical Center, Nashville

39008

Hospital Universitario Marques de Valdecilla, Santander

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

48109

University of Michigan, Ann Arbor

53792

University of Wisconsin, Carbone Cancer Center, Madison

55905

Mayo Cancer Center, Rochester

60611

Northwestern University, Chicago

60637

University of Chicago Medical Center, Chicago

63110

Washington University, St Louis

75390

University of Texas, SouthWestern, Dallas

77030

UT MD Anderson Cancer Center, Houston

84112

University of Utah, Huntsman Cancer Institute, Salt Lake City

85054

Mayo Cancer Center, Scottsdale

90033

University of Southern California, Los Angeles

91010

City of Hope Cancer Center, Duarte

92868

University of California, Irvine, Irvine

94158

University of California, San Francisco, San Francisco

94805

Institut Gustave Roussy, Villejuif

98109

Seattle Cancer Care Alliance, Seattle

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

03080

Seoul National University Hospital, Seoul

03722

Yonsei University Severance Hospital, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

06591

Seoul, St. Mary's Hospital, Seoul

08035

Hospital Vall d'Hebrón, Barcelona

LS16 6QB

St. James University Hospital, Leeds

CH63 4JY

Liverpool Cancer Center, Liverpool

NW1 2PG

University College London Hospitals, London

NW3 2QG

The Royal Free Hospital, London

M20 4QL

The Christie NHS Foundation Trust, the Christie Hospital, Manchester

All Listed Sponsors
lead

Institut de Recherches Internationales Servier

OTHER

NCT02989857 - Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) | Biotech Hunter | Biotech Hunter